Freeline Therapeutics Holdings PLC
https://www.freeline.life/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Freeline Therapeutics Holdings PLC
Syncona Buys Out Ailing Gene Therapy Company Freeline
Syncona has stepped in to save Freeline and give it more time to prove the value of FLT201, its early-stage Gaucher’s disease gene therapy.
Finance Watch: PTC Raises $1bn In Evrysdi Royalty Deal Weeks After Latest Layoffs
Public Company Edition: PTC sold more of its Evrysdi royalties to Royalty Pharma for $1bn. Abivax gained $235.8m in an IPO and concurrent private placement, while Cerevel grossed $450m and Nuvalent and Ultragenyx raised $300m each in follow-on offerings, but Freeline is reviewing strategic options.
In Seeking ‘Strategic Alternatives’ Avrobio Is Confronting Gene Therapy Reality
Avrobio is facing up to the reality of investor skepticism about gene therapy platforms and business models – but can it find a buyer or merger partner to start again?
Finance Watch: Vertex Ventures, Chugai Each Raise New $200m VC Funds
Private Company Edition: Vertex Ventures (not Vertex Pharmaceuticals) closed its third fund, with $200m for life science and medical technologies, while Chugai’s $200m corporate VC fund will invest in drug discovery start-ups. Also, K36 closed a $70m series B round and Attovia launched with $60m.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice